Placid Jover - 01 Aug 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: Executive Vice President, Chief Human Resources Officer.
Signature: /s/ Dov Bergwerk as attorney-in-fact for Placid Jover
Issuer symbol: TEVA
Transactions as of: 01 Aug 2025
Net transactions value: -$91,748
Form type: 4
Filing time: 05 Aug 2025, 16:04:57 UTC
Previous filing: 07 Mar 2025
Next filing: 06 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Jover Placid	Executive Vice President, Chief Human Resources Officer.	C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL	/s/ Dov Bergwerk as attorney-in-fact for Placid Jover	05 Aug 2025	0002026165

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TEVA	Ordinary Shares	Options Exercise		+12,827			12,827	01 Aug 2025	Direct	F1, F2
transaction	TEVA	Ordinary Shares	Sale	$91,748	-6,053	-47%	$15.16	6,774	01 Aug 2025	Direct	F1, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Options Exercise	$0	-12,827	-25%	$0.000000	38,484	01 Aug 2025	Ordinary Shares	12,827		Direct	F1, F2, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3	Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.13 to $15.31, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5	Restricted share units were granted on August 1, 2024, with 12,827 vested on August 1, 2025, 12,827 vesting on each of August 1, 2026 and August 1, 2027, and 12,830 vesting on August 1, 2028.

Remarks:

Executive Vice President, Chief Human Resources Officer.